Shipping to United States We Offer Worldwide Shipping
Login Wishlist

Roxithromycin

$52

  • Brand : BIOFRON

  • Catalogue Number : BD-P0678

  • Specification : 98.0%(HPLC)

  • CAS number : 80214-83-1

  • Formula : C41H76N2O15

  • Molecular Weight : C41H76N2O15

  • Volume : 25mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BD-P0678

Analysis Method

Specification

98.0%(HPLC)

Storage

2-8°C

Molecular Weight

C41H76N2O15

Appearance

Botanical Source

Structure Type

Other Alkaloids

Category

SMILES

CCC1C(C(C(C(=NOCOCCOC)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O

Synonyms

Roxid/Overal/Forilin/Roxithromycin/Claramid/biaxsig/RU 965/Assoral/roxyithromycin/Brilid/(3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-10-{[(2-methoxyethoxy)methoxy]imino}-3,5,7,9,11,13-hexamethyloxacyclotetradecan-2-one/Rulid/Surlid

IUPAC Name

Applications

Density

1.3±0.1 g/cm3

Solubility

Methanol; Chloroform

Flash Point

476.7±37.1 °C

Boiling Point

864.7±75.0 °C at 760 mmHg

Melting Point

115- 120ºC

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:80214-83-1) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

31694095

Abstract

Objective: To explore the role of S100A8, the receptor for advanced glycation endproducts (RAGE) and Caveolin-1 in neutrophilic asthmatic rats, and to further study the intervention of roxithromycin and the possible mechanisms. Methods: Male Brown Norway rats were randomly assigned to a control group, an asthma group and a Roxithromycin group. The asthmatic rat model was established by intraperitoneal injection of ovalbumin (OVA) and Freund’s complete adjuvant (FCA) mixture, and aerosol inhalation of OVA. Rats in the Roxithromycin group were given roxithromycin injection 30 mg/kg 30 minutes before each challenge. Rats in the control and the asthma groups were replaced with equal volumes of saline, respectively. Bronchoalveolar lavage fluid (BALF) neutrophil percentage (Neu%) and pathological changes of pulmonary tissue (hematoxylin-eosin, HE staining) were measured to confirm the establishment of asthmatic models. The concentration of inflammatory cytokines and S100A8 were quantified by enzyme-linked immunosorbent assay (ELISA), and the expression of Caveolin-1 and RAGE at protein levels were detected by immunohistochemistry and Western blot. Results: Neu% in BALF of the asthma group was significantly higher than those of the control group, and Neu% in the Roxithromycin group was lower than the asthma group (all P<0.01). Pulmonary histology revealed that there were a large number of inflammatory cells infiltrated in the bronchial and perivascular, pulmonary interstitial and alveolar spaces, and the bronchial wall and smooth muscles were thickened obviously in the asthma group. Rats in the Roxithromycin group showed milder inflammation and airway remodeling change than the asthma group. There was no obvious pathological damage in the control group. The concentration of IL-6 and IL-17 in BALF and serum of rats in the asthma group were significantly higher than those in the control group (P<0.01), and Roxithromycin inhibited the high expression of these cytokines (P<0.05). The expression of S100A8 and RAGE in the asthma group were significantly higher than those in the control group [(20.6±4.4) vs (7.1±2.0) ng/L; (885±118) vs (462±102) ng/L; (14.2±1.7) vs (7.6±1.8) ng/L; (774±166) vs (406±69) ng/L, all P<0.05], and Roxithromycin inhibited the high expression of these proteins [(14.3±3.7) vs (20.6±4.4) ng/L; (650±53) vs (885±118) ng/L; (10.4±1.2) vs (14.2±1.7) ng/L; (560±64) vs (728±72) ng/L] (all P<0.05). Meanwhile, the expression of Caveolin-1 in the asthma group was significantly lower than that in the control group (P<0.01), and Roxithromycin up-regulated its expression (P<0.01). Correlation analysis showed that there was a significantly positive correlation between the expression of S100A8 and RAGE (r=0.706, P<0.01), while there was a significantly negative correlation between the expression of S100A8 and Caveolin-1 (r=-0.775, P<0.01), and between the expression of Caveolin-1 and RAGE (r=-0.919, P<0.01). Conclusion: S100A8 and Caveolin-1 may play an important role in neutrophilic asthma via RAGE, and Roxithromycin may exerts anti-inflammatory effects and inhibition of airway remodeling partly through this signaling pathway.

KEYWORDS

Airway remodeling; Asthma; Calgranulin A; Inflammation; Neutrophil; Roxithromycin

Title

[The role of S100A8/RAGE and Caveolin-1 and the effect of roxithromycin on their expression in a rat model of neutrophilic asthma].

Author

Gu XF1, Chen XM1, Chen HJ2, Xu TT1, Qiu ZW1, Sun DD3, Ge XT1, Ying SM4, Dai YR1.

Publish date

2019 Nov 12

PMID

31484284

Abstract

Objective: To observe the expression of the Receptor of Advanced glycation end products (RAGE) in asthmatic rats, and explore the intervention of Roxithromycin. Methods: A total of 18 Specific Pathogen Free-class Brown Norway male rats were randomly divided into control group, asthma model group and Roxithromycin group, with 6 rats in each group. The asthmatic model was sensitized by intraperitoneal injection of Ovalbumin (OVA)+Al(OH)(3), and challenged with OVA. Rats in Roxithromycin group were given Roxithromycin 30 mg/kg 30 minutes before each challenge. Rats in control group and asthma model group were treated with equal volume of saline. The concentrations of RAGE and interleukin (IL)-4 in serum and bronchoalveolar lavage fluid (BALF) were measured by enzyme-linked immunosorbent (ELISA); the pathological changes of lung tissues were observed by HE-staining; the thickness of airway wall and airway smooth muscle were measured by Image-Pro Plus; the relative expression of RAGE in lung tissues were detected by Western blot. Results: In asthma model group, the concentrations of RAGE and IL-4 in the serum and BALF were obviously higher than those in control group [(494±32) vs (327±45) ng/L; (32.4±5.8) vs (13.1±2.9) ng/L; (553±38) vs (399±56) ng/L; (37.8±3.4) vs (19.4±2.5) ng/L] (all P<0.01); in Roxithromycin group, the concentrations of RAGE and IL-4 in the serum and BALF were obviously lower than those in asthma model group [(438±18) vs (494±32) ng/L; (22.8±6.0) vs (32.4±5.8) ng/L; (444±42) vs (553±38) ng/L; (25.6±4.5) vs (37.8±3.4) ng/L] (all P<0.05). In asthma model group, the bronchial wall was thickened, the lumen was narrow, the mucosal wrinkles were significantly increased, edema appeared under the mucosa, and a large number of inflammatory cells infiltrated and aggregated in the bronchi, perivascular and alveolar spaces; the thickness of airway wall and airway smooth muscle were significantly increased than those in control group (P<0.01); in Roxithromycin group, airway inflammation and remodeling were alleviated compared with those in asthma model group (P<0.05). In asthma model group, the expression of RAGE in lung tissues were significantly increased than those in control group (P<0.01); in Roxithromycin group, the expression of RAGE were significantly decreased than those in asthma model group (P<0.01). There were positive correlations between the expression of RAGE and IL-4 in BALF and serum (r=0.782, 0.804, all P<0.01); there were positive correlations between RAGE and total white cell counts, eosinophil counts, smooth muscle thickness (r=0.897, 0.927, 0.860, all P<0.01). Conclusions: The increasing of RAGE in asthmatic rats are positively correlated with airway inflammation and airway remodeling. Roxithromycin may inhibit the development of asthma by reducing the expression of RAGE.

KEYWORDS

Asthma; Glycation end products, advanced; Rats; Roxithromycin

Title

[Expression of RAGE in asthmatic rats and the intervention of Roxithromycin].

Author

Gu XF1, Chen HJ2, Chen XM1, Xu TT1, Qiu ZW1, Wu LQ1, Dai W3, Ying SM4, Dai YR1.

Publish date

2019 Aug 27

PMID

31377929

Abstract

The pharmaceutical and personal care product (PPCP) residues in freshwater lakes are being highlighted around the world. The occurrence and ecological risk of 34 PPCPs classified as antibiotics, non-steroidal anti-inflammatory drugs (NSAID), cardiovascular drugs, psychotropic drugs, anti-inflammatory drugs, psychostimulants, and pesticides during rainstorm period in surface water of the Dongting Lake, China, were studied. Twenty-six out of thirty-four PPCPs were detected, and the total concentrations of antibiotics ranged from 0.15 to 214.75 ng L-1 in surface water. The highest average concentration was observed for diclofenac, followed by diethyltoluamide (DEET). The PPCP concentrations were much lower in Dongting Lake compared to other rivers and lakes due to the strong dilution effect of rainstorm, while the detection rate remains high. Caffeine and DEET were detected with 100% frequency in Dongting Lake, and the detection rates of diclofenac, mefenamic acid, and roxithromycin were above 90%. The pollution levels of antibiotics decreased in the order of East Dongting Lake > South Dongting Lake > West Dongting Lake, which may be related to the distribution of aquaculture plants, sewage treatment plants, and population density. The risk quotient (RQ) method was used to evaluate ecological environment risk under the worst case and the results suggested that clarithromycin, diclofenac, roxithromycin, and erythromycin might pose a significant risk to aquatic organisms in Dongting Lake, especially clarithromycin. This study can provide data support for further research on the dilutive effect and mechanism of rainwater runoff on PPCPs in lakes on a large scale.

KEYWORDS

Dongting Lake; Ecological risk; PPCPs; Rainstorm; Surface water

Title

Occurrence and ecological risk of pharmaceutical and personal care products in surface water of the Dongting Lake, China-during rainstorm period.

Author

Wang Y1,2, Liu Y1, Lu S3, Liu X2,4, Meng Y5, Zhang G1, Zhang Y1, Wang W1, Guo X2.

Publish date

2019 Oct